Core Insights - TransDigm Group Incorporated (TDG) is expected to report its third-quarter fiscal 2025 results on August 5, with a trailing four-quarter average earnings surprise of 5.13% [1][6] - The growth in commercial air travel and strong defense sales are anticipated to positively impact the quarterly performance [1] Segment Performance - The Power & Control segment is projected to generate revenues of $1.20 billion, reflecting a 17.1% increase from the previous year, driven by strong commercial aftermarket sales and improved defense spending [2][3] - The Airframe segment is expected to report revenues of $1.06 billion, indicating a 9% growth year-over-year, supported by rising demand for defense products and increased air travel [4][8] Overall Financial Expectations - The overall sales for TDG in the fiscal third quarter are estimated at $2.30 billion, representing a 12.2% improvement compared to the prior year [5][8] - Earnings per share are projected to be $9.78, which is an 8.7% increase from the same quarter last year, aided by strong revenue growth and cost reduction initiatives [6] Earnings Prediction - The Zacks model indicates a likely earnings beat for TDG, with an Earnings ESP of +0.40% and a Zacks Rank of 2 (Buy) [7][9]

Core Viewpoint - Allison Transmission Holdings, Inc. is expected to report second-quarter 2025 results on August 4, with sales and earnings estimates of $794.43 million and $2.20 per share respectively [1][8] Financial Performance - The earnings projection indicates a year-over-year increase of 3.29%, while the revenue estimate suggests a decline of 2.64% compared to the previous year [2] - In the first quarter of 2025, Allison reported adjusted earnings of $2.23 per share, exceeding the Zacks Consensus Estimate of $1.97, and reflecting a 17% year-over-year increase. However, quarterly revenues of $766 million fell 3% from the previous year and missed the consensus estimate of $775 million [2] Market Demand and Outlook - Strong demand for Class 8 vocational vehicles in the North America On-Highway market is driving revenue growth, with expectations to continue this trend into 2025. The company anticipates adjusted EBITDA between $1.17 billion and $1.23 billion for 2025, an increase from $1.165 billion in 2024, and net income projected between $735 million and $785 million, up from $731 million in 2024 [3] R&D and Cost Pressures - The company's electrified propulsion initiatives are expected to increase spending levels, impacting cash flows. R&D costs rose approximately 3% year-over-year in 2024 due to higher spending on product initiatives, and further increases in R&D expenses are anticipated in 2025 [4] Earnings Prediction - The current model does not predict an earnings beat for Allison in the upcoming quarter, as it lacks the necessary combination of positive Earnings ESP and a favorable Zacks Rank [5] - Allison has an Earnings ESP of -0.41% and currently holds a Zacks Rank of 3 [6]

Key Takeaways Cboe Global Markets, Inc. (CBOE) is expected to register an improvement in its top and bottom lines when it reports second-quarter 2025 results on Aug. 1, before the opening bell. The Zacks Consensus Estimate for CBOE's second-quarter revenues is pegged at $572.24 million, indicating 11.3% growth from the year-ago reported figure. Zacks Rank: CBOE carries a Zacks Rank #3 at present. Factors Likely to Shape Q2 Results of CBOE Solid index options growth, higher transaction and clearing fees, acc ...

Core Insights - Mastercard is expected to report Q2 2025 earnings on July 31, 2025, with an estimated EPS of $4.05 and revenues of $7.99 billion, reflecting year-over-year increases of 12.8% and 14.7% respectively [1][2][8] Financial Performance - The full-year 2025 revenue estimate for Mastercard is $31.96 billion, indicating a 13.5% year-over-year growth, while the EPS estimate is $16.04, suggesting a 9.9% increase [3] - Mastercard has consistently surpassed earnings estimates, achieving an average surprise of 3.7% over the last four quarters [4] Earnings Predictions - The company is projected to experience growth in switched transactions, cross-border volumes, and value-added services, contributing to its Q2 performance [8] - The Gross Dollar Volume (GDV) is expected to rise by 7.4% year-over-year, with domestic operations increasing by nearly 7% and international operations by 6% [9] - Switched transactions are anticipated to grow by 10.4% year-over-year, driven by consumer spending and contactless payment initiatives [10] - Cross-border volumes are expected to increase by 17.1%, with domestic assessments and transaction processing assessments projected to rise by 10.2% and 13.5% respectively [11] Cost and Margin Considerations - Adjusted operating expenses are expected to rise nearly 16% year-over-year, influenced by higher general and administrative costs as well as advertising and marketing expenses [14] - Payments network rebates and incentives are projected to increase by 12.6% year-over-year, which may impact margins despite strong revenue growth [14][13] Stock Performance and Valuation - Mastercard's stock has gained 8% year-to-date, outperforming the industry average of 4.7% [15] - The current forward P/E ratio for Mastercard is 32.33, above its five-year median of 31.74 and the industry average of 22.19 [17] - Competitors Visa and American Express are trading at lower forward P/E ratios of 28.31 and 18.85 respectively, indicating better value [19] Strategic Outlook - Mastercard is enhancing its competitive edge through digital capabilities, merchant engagement, and customer experience improvements [20] - The company is focusing on tokenized transactions and stablecoin infrastructure as part of its innovative strategy [20] - Value-added services are expected to remain a significant growth driver, supported by robust cash flows for dividends and strategic investments [20]

Core Viewpoint - Linde plc is expected to report its second-quarter 2025 results on August 1, with earnings per share estimated at $4.03 and revenues at $8.35 billion, reflecting a year-over-year improvement in earnings and revenues [1][3][9]. Group 1: Q1 Performance and Expectations - In the previous quarter, Linde's earnings were $3.95 per share, surpassing the Zacks Consensus Estimate of $3.93, driven by higher pricing and increased volumes from the Americas segment [2]. - The Zacks Consensus Estimate for second-quarter earnings per share is $4.03, indicating a 4.68% improvement from the prior-year quarter [2]. - The expected revenue for the second quarter is $8.35 billion, which represents a year-over-year increase of 1.04% [3]. Group 2: Market Position and Performance Factors - Linde is a global leader in industrial gas production, serving various end markets including healthcare, manufacturing, and chemicals & refining [4]. - The company is anticipated to maintain stable performance due to long-term contracts with major on-site clients and operations in resilient end markets such as healthcare and food and beverages [5]. - However, challenges may arise from tariffs and changes in trade policies, which could slow down industrial activity globally, particularly affecting demand in markets like China and Europe [6]. Group 3: Segment Performance Estimates - The Zacks Consensus Estimate for operating profit in the Americas segment is $1.19 billion, an increase from $1.16 billion in the second quarter of 2024 [7]. - The operating profit estimate for the Engineering business unit is $100 million, up from $96 million a year ago [7]. - These factors are expected to influence demand and pricing dynamics, potentially impacting Linde's quarterly performance [7].

Core Viewpoint - Vertex Pharmaceuticals (VRTX) is expected to exceed expectations in its second-quarter 2025 results, with projected revenues of $2.89 billion and earnings of $4.24 per share [1][2]. Group 1: Sales Performance - Vertex's cystic fibrosis (CF) franchise sales are growing, primarily driven by increased sales of its CF medicine, Trikafta/Kaftrio, particularly in younger age groups [3][7]. - Strong demand for Trikafta/Kaftrio in the U.S. is anticipated to drive revenues, although international sales faced challenges due to illegal copy products in Russia [4][5]. - Trikafta/Kaftrio sales estimates are $2.56 billion according to Zacks Consensus and $2.50 billion based on internal models, with potential sales erosion from other CF drugs [5][9]. Group 2: New Product Developments - Vertex's new gene therapy, Casgevy, approved for sickle cell disease and beta-thalassemia, recorded $14.2 million in sales in Q1 2025, with a sequential increase of 77.5% expected in Q2 [8][9]. - The fifth CF medicine, Alyftrek, generated $53.9 million in sales in Q1 2025, with steady uptake noted, although the switch from Trikafta to Alyftrek has been slower than anticipated [10][11]. - Journavx, a non-opioid pain medicine, was recently approved but had insignificant sales in the last quarter, with expectations for improvement in the second half of the year [12]. Group 3: Earnings Expectations - Vertex's earnings surprise history shows a mixed performance, with one earnings beat in the last four quarters and an average negative surprise of 2.39% [14]. - The company's Earnings ESP is +1.82%, indicating a potential earnings beat, supported by a Zacks Rank of 3 [15][16].

Core Viewpoint - Moderna (MRNA) is expected to exceed earnings expectations for Q2 2025, with a prior earnings surprise of 13.70% in the last quarter. The consensus estimates for sales and earnings are $127 million and a loss of $2.99 per share, respectively [1][9]. Factors Shaping MRNA's Upcoming Results - A significant portion of Moderna's revenue is anticipated to come from the COVID-19 vaccine, Spikevax, with estimated sales of $59 million, reflecting a notable decline from the previous year due to reduced demand [2]. - Minimal sales are expected from the RSV vaccine, mResvia, with projections of only $2 million, which is considerably lower than competing products from GSK and Pfizer. This is attributed to the later approval and recommendation of the vaccine [3]. Regulatory Developments - The FDA has expanded the label for mResvia to include high-risk adults aged 18-59, and the CDC has updated its recommendations for RSV vaccines to include high-risk adults aged 50-59. Investors are looking for updates on marketing strategies for both vaccines [4]. - A regulatory filing is under FDA review to update Spikevax for the LP.8.1 variant for the 2025-26 vaccination season, with a similar filing also under review by the EMA. Investors are keen on updates regarding these regulatory processes [5]. Pipeline Candidates - Moderna is advancing several late-stage pipeline candidates, including the influenza vaccine candidate mRNA-1010, which has shown superior efficacy compared to an approved flu shot. This supports potential approval for a standalone flu shot and strengthens the case for the combination vaccine mRNA-1083 [6]. - An important candidate is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, currently evaluated in pivotal phase III studies for various cancer indications. Investors are interested in updates on this therapy's progress [7]. Earnings Surprise History - Moderna has consistently beaten earnings estimates over the past four quarters, achieving an average surprise of 31.60% [8]. Market Performance - Year to date, Moderna's shares have declined by 18%, contrasting with a 2% growth in the industry [10].

Core Viewpoint - Eversource Energy (ES) is expected to report its second-quarter 2025 results on July 31, with earnings anticipated to be in line with estimates, reflecting various operational factors that may influence performance [1][10]. Group 1: Factors Impacting Q2 Performance - Eversource Energy's focus on being a pure-play regulated utility is likely to support its clean energy transition efforts, contributing positively to quarterly earnings [2]. - The integration of probabilistic load flow (PLF) automation into its power system analysis is expected to enhance service reliability and boost earnings through improved distribution modeling capabilities [3]. - New electric and gas rates implemented in the service regions during the first and previous quarters are anticipated to positively impact the bottom line, along with increased transmission investments and lower operation and maintenance expenses [4]. Group 2: Expected Financial Metrics - The Zacks Consensus Estimate for Eversource Energy's earnings is set at 95 cents per share, remaining flat year over year, while revenues are estimated at $2.90 billion, indicating a year-over-year increase of 14.7% [6][10]. - The company's Earnings ESP is +0.26%, suggesting a favorable outlook for an earnings beat in the upcoming report [7]. Group 3: Potential Challenges - Higher depreciation and property taxes due to increased investments, along with rising interest expenses and a higher effective tax rate, are expected to negatively affect overall quarterly performance [5][10].

Core Insights - Robinhood Markets (HOOD) is expected to announce its second-quarter 2025 results on July 30, following a strong first-quarter performance driven by increased equity trading, higher net interest revenues, and a rise in Gold subscribers [1][2] - The consensus estimate for Q2 2025 sales is $915.2 million, reflecting a 34.2% year-over-year increase, with transaction-based revenues projected to rise significantly [2][9] Financial Performance - In Q1 2025, Robinhood reported earnings of $0.37 per share, surpassing estimates by 19.35%, and has a history of beating earnings estimates in three of the last four quarters [3][5] - The consensus estimate for Q2 earnings is 31 cents, indicating a 47.6% increase from the same quarter last year [5][7] Revenue Breakdown - Q2 revenue is anticipated to rise 34.2% year-over-year to $915.2 million, with transaction-based revenues expected to jump 55.5% [9][10] - Options transaction revenues are estimated at $252.2 million, suggesting a 38.6% growth, while equity and cryptocurrency transaction revenues are projected to increase by 70.2% and 93.2%, respectively [11][12] Operating Expenses - Total operating expenses are expected to remain high due to investments in platform capabilities, product innovation, and merger-related charges from the acquisition of WonderFi Technologies [13] Market Position and Valuation - Robinhood's stock has increased by 151.3% in the first half of 2025, outperforming industry growth [16] - Currently, HOOD trades at a price-to-tangible book (P/TB) ratio of 12.62, significantly above its three-year median of 5.05 [19] Strategic Initiatives - The company is focusing on expanding its operations and diversifying its product offerings, particularly in the cryptocurrency space and international markets [22][23] - Robinhood's initiatives to enhance its product suite and reduce reliance on transaction-based revenue reflect its growing maturity as a business [23] Investment Outlook - Despite regulatory scrutiny and competition in the banking sector, Robinhood's strategic acquisitions and product diversification efforts position it well for strong Q2 results [26][27] - The current market conditions may present an opportune time for investment ahead of the upcoming earnings release [27]

Core Viewpoint - The Hartford Insurance Group, Inc. (HIG) is expected to report second-quarter 2025 results on July 28, with earnings estimated at $2.77 per share and revenues at $4.89 billion, indicating year-over-year growth in both metrics [1][2][6]. Financial Performance - The second-quarter earnings estimate has decreased by 1 cent over the past 60 days, but still reflects a year-over-year increase of 10.8% [2]. - The Zacks Consensus Estimate for full-year 2025 revenues is $19.8 billion, representing an 8.4% year-over-year rise, while the EPS estimate is $10.93, indicating a 6.1% increase year-over-year [3]. - HIG has consistently beaten consensus estimates in the last four quarters, with an average surprise of 6.4% [3]. Earnings Predictions - The company is predicted to achieve an earnings beat this quarter, supported by a positive Earnings ESP of +0.32% and a Zacks Rank of 3 (Hold) [4]. - The consensus estimate for net premiums earned in Q2 indicates a 7.9% year-over-year growth, alongside an 11.7% increase in net investment income [5][6]. Segment Performance - Personal Insurance pre-tax income is projected to recover to $79.9 million from a loss of $15 million in the previous year [6][9]. - The homeowners' policies in force are expected to grow by 2% year-over-year, while small commercial policies are projected to increase by 5%. However, automobile policies are anticipated to decline by 6% [7]. Ratios and Metrics - The Personal Insurance combined ratio is estimated at 99.44%, showing improvement from the previous year's 107.40%, while the expense ratio is expected to rise slightly to 26.73% from 26.40% [8].